Abstract:BACKGROUND: As newer oral diabetes agents continue to emerge on the market, comparative evidence is urgently required to guide appropriate therapy.PURPOSE: To summarize the English-language literature on the benefits and harms of oral agents (second-generation sulfonylureas, biguanides, thiazolidinediones, meglitinides, and alpha-glucosidase inhibitors) in the treatment of adults with type 2 diabetes mellitus.DATA SOURCES: The MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched from inception through January 2006 for original articles and through November 2005 for systematic reviews. Unpublished U.S. Food and Drug Administration and industry data were also searched.STUDY SELECTION: 216 controlled trials and cohort studies and 2 systematic reviews that addressed benefits and harms of oral diabetes drug classes available in the United States.DATA EXTRACTION: Using standardized protocols, 2 reviewers serially abstracted data for each article.DATA SYNTHESIS: Evidence from clinical trials was inconclusive on major clinical end points, such as cardiovascular mortality. Therefore, the review was limited mainly to studies of intermediate end points. Most oral agents (thiazolidinediones, metformin, and repaglinide) improved glycemic control to the same degree as sulfonylureas (absolute decrease in hemoglobin A1c level of about 1 percentage point). Nateglinide and alpha-glucosidase inhibitors may have slightly weaker effects, on the basis of indirect comparisons of placebo-controlled trials. Thiazolidinediones were the only class that had a beneficial effect on high-density lipoprotein cholesterol levels (mean relative increase, 0.08 to 0.13 mmol/L [3 to 5 mg/dL]) but a harmful effect on low-density lipoprotein (LDL) cholesterol levels (mean relative increase, 0.26 mmol/L [10 mg/dL]) compared with other oral agents. Metformin decreased LDL cholesterol levels by about 0.26 mmol/L (10 mg/dL), whereas other oral agents had no obvious effects on LDL cholesterol levels. Most agents other than metformin increased body weight by 1 to 5 kg. Sulfonylureas and repaglinide were associated with greater risk for hypoglycemia, thiazolidinediones with greater risk for heart failure, and metformin with greater risk for gastrointestinal problems compared with other oral agents. Lactic acidosis was no more common in metformin recipients without comorbid conditions than in recipients of other oral diabetes agents.LIMITATIONS: Data on major clinical end points were limited. Studies inconsistently reported adverse events other than hypoglycemia, and definitions of adverse events varied across studies. Some harms not assessed in trials or observational studies may have been overlooked.CONCLUSIONS: Compared with newer, more expensive agents (thiazolidinediones, alpha-glucosidase inhibitors, and meglitinides), older agents (second-generation sulfonylureas and metformin) have similar or superior effects on glycemic control, lipids, and other intermediate end points. Large, long-term comparative studies are needed to determine the comparative effects of oral diabetes agents on hard clinical end points.

Comparison of clinical review and regulation for biologics and chemical drugs of FDA:a case study of type 2 diabetes mellitus

Opinions and suggestions of bioequivalent studies on modified new drugs

PDG8 EFFICACY OF PHARMACOLOGICAL MONOTHERAPIES FOR TYPE 2 DIABETES IN CHINA

PP93 Efficacy of Pharmacological Treatments for Type 2 Diabetes in China

Efficacy of Pharmacological Monotherapies for Type 2 Diabetes in China: A Systematic Review and Meta-Analysis

Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

Efficacy and Safety of Basal Analog Regimens in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Pharmacological Combination Therapies for the Treatment of Type 2 Diabetes in China: A Systematic Review and Meta-Analysis

Comparative Efficacy and Safety of Long-Acting Insulin Analogs in Patients with Type 2 Diabetes Failing on Oral Therapy: Systemic Review and Meta-Analyses

Assessment of the differences between generic and biosimilar drugs: A brief literature review

Comparison of Glucose-Lowering Drugs As Second-Line Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis

Autologous stem cell transplantation in hematological malignancies

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Review of the regulations for clinical research in herbal medicines in USA

Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues

Comparative effectiveness and safety of different basal insulins in a real-world setting.

Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis

The Correlations Between Steady-State Concentration, Duration of Action and Molecular Weight of GLP-1RAs and Their Efficacy and Gastrointestinal Side Effects in Patients with Type 2 Diabetes Mellitus: a Systematic Review and Meta-Analysis

Determining Equivalence for Generic Locally Acting Drug Products

Benchmarking the medication efficiency and technological progress of diabetes drugs

A comprehensive review on registration requirements for Drug Approval in India, South Africa and US